Drug Profile
VPX 638
Alternative Names: VPX-638Latest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center; Vapogenix
- Developer Vapogenix
- Class Anaesthetics; Analgesics; Non-opioid analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Pain
Highest Development Phases
- Phase II Pain
Most Recent Events
- 23 Feb 2022 VPX 638 is still in phase II trials for Pain in Australia
- 11 Nov 2020 Vapogenix receives SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for VPX 638 development in Pain
- 11 Nov 2020 Vapogenix has patent protection for VPX 638 formulation for painful inflammatory conditions